A5070370202- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Thyroid Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- MicroRNA in disease regulation
- Pleural and Pulmonary Diseases
- Computational Drug Discovery Methods
- Pancreatic and Hepatic Oncology Research
- Ovarian cancer diagnosis and treatment
- Occupational and environmental lung diseases
Fondazione IRCCS Istituto Nazionale dei Tumori
2019-2022
Institut d'Investigació Biomédica de Bellvitge
2012
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2012
University of Turin
2012
•ctDNA was detected in 77% of early-stage TNBC patients undergoing neoadjuvant chemotherapy.•Patients with still detectable ctDNA after NAC were more than twice as likely to relapse those undetectable levels.•Detection during follow-up antedated clinical overt metastases up 13 months.•ctDNA all but one non-recurrent patient a temporary peak only 1 8 samples tested.•CTCs progressing cases lacked epithelial surface markers and showed therapeutically exploitable molecular features. BackgroundAs...
PURPOSE Prognostic tools to estimate the risk of relapse for patients with liver-limited metastatic colorectal cancer (LL-mCRC) undergoing resection curative intent are needed. Circulating tumor DNA (ctDNA) as a surrogate postsurgical minimal residual disease is promising marker in localized CRC. We explored role postoperative ctDNA radically resected LL-mCRC. MATERIALS AND METHODS Seventy-six LL-mCRC were retrospectively included. from tissue was sequenced, and one somatic mutation then...
Physical examinations and annual mammography (minimal follow-up) are as effective laboratory/imaging tests (intensive in detecting breast cancer (BC) recurrence. This statement is now challenged by the availability of new diagnostic tools for asymptomatic cases. Herein, we analyzed current practices circulating tumor DNA (ctDNA) monitoring high-risk BC patients treated with curative intent a comprehensive center.Forty-two consecutive triple negative undergoing neoadjuvant therapy surgery...
e18577 Background: ATC is a very aggressive disease. In the last years new insights on molecular profile of have led to novel therapeutic options, primarily BRAF-targeted agents. Methods: From May 2018 December 2019, data recurrent/metastatic patients treated at our Institution been reviewed. BRAF V600E was assessed in each patient. mutation tested both tumor sections and cell-free DNA (cfDNA). Circulating by using Droplet Digital PCR (ddPCR) Technology. wild-type (WT) were with standard...
Background: Biomarker/s able to detect minimal residual disease (MRD) after breast cancer (BC) surgery are needed aid optimal systemic therapy. We aimed at investigating the feasibility of using circulating tumor DNA (ctDNA) early MRD in plasma samples collected during follow-up patients (pts) with BC. Methods: Forty BC pts undergoing curative intent and regular for a minimum 13 years were included 1:3 case-control study. Preliminary experiments demonstrated that heparinase I digestion does...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)